Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient.

Fiche publication

Date publication

octobre 2021




Membres identifiés du Cancéropôle Est :
Pr KOHLI Evelyne

Tous les auteurs :
Michiels Y, Houhou-Fidouh N, Collin G, Berger J, Kohli E


Patients with multiple sclerosis (MS) are treated with drugs that may impact immune responses to SARS-CoV-2 vaccination. Evaluation of "prime-boost" (heterologous) vaccination regimens including a first administration of a viral vector-based vaccine and a second one of an mRNA-based vaccine in such patients has not yet been completed. Here, we present the anti-spike protein S humoral response, including the neutralizing antibody response, in a 54-year-old MS patient who had been treated with teriflunomide for the past 2 years and who received a heterologous ChAdOx1 nCoV-19/ BNT162b2 vaccination regimen. The results showed a very strong anti-S IgG response and a good neutralizing antibody response. These results show that teriflunomide did not prevent the development of a satisfactory humoral response in this MS patient after vaccination with a ChAdOx1 nCoV-19/ BNT162b2 prime-boost protocol.

Mots clés

BNT162b2 vaccine, ChAdOx1 nCoV-19 vaccine, SARS-CoV-2, antibody response, teriflunomide


Vaccines (Basel). 2021 Oct 6;9(10):